Skip to main content

Table 1 Patient characteristics

From: Perioperative clinical and economic outcomes associated with replacing first-generation high molecular weight hydroxyethyl starch (Hextend®) with low molecular weight hydroxyethyl starch (Voluven®) at a large medical center

 

2009 ( n= 2,098)

2010 ( n= 2,790)

P value

Total N

Mean or n

SD or percentage

Total N

Mean or n

SD or percentage

Age (yrs) (mean, SD)

2,098

58.1

15.4

2,790

58

15.6

0.8910

Female gender (n,%)

1,972

902

45.7

2,767

1,343

48.5

0.0574

Race (n,%)

1,966

  

2,762

  

0.7380

 White

 

1,454

74

 

2,043

74

0.9933

 Black

 

430

21.9

 

601

21.8

0.9266

 Nat. Amer

 

23

1.2

 

26

0.9

0.4444

 Asian

 

21

1.1

 

22

0.8

0.3322

 Other

 

35

1.8

 

65

2.4

0.1621

 Multiracial

 

3

0.2

 

5

0.2

1.0000

BMI (mean, SD)

1,884

29.6

7.3

2,639

29.5

7.3

0.9510

CAD preop (n,%)

1,383

721

52.1

1,839

1,016

55.2

0.0792

COPD preop (n,%)

1,383

83

6

1,839

116

6.3

0.7207

CABG preop (n,%)

1,383

9

0.7

1,839

12

0.7

0.9951

MI preop (n,%)

1,383

21

1.5

1,839

29

1.6

0.8942

Preop valve dz (n,%)

1,383

48

3.5

1,839

67

3.6

0.7938

Diabetes type I (n,%)

1,383

6

0.4

1,839

11

0.6

0.6274

Diabetes type II (n,%)

1,383

224

16.2

1,839

331

18

0.1799

Hypertension preop (n,%)

1,383

721

52.1

1,839

1,016

55.2

0.0792

Preop creatinine (mean, SD)

1,370

1

0.6

1,847

1.1

1.3

0.1725

  1. yrs, years; Nat. Amer, Native American; BMI, body mass index; h/o, history of; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; Preop valve dz, preoperative valve disease; CABG, coronary artery bypass graft; MI, myocardial infarction; DM, diabetes mellitus; preop, preoperative; SD, standard deviation.